|
[1]De FRANCESCO R, CARFA.Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus[J].Adv Drug Deliv Rev, 2007, 59 (12) :1242-1262.
|
|
[2]FLAMM SL, LAWITZ E, JACOBSON I, et al.Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection[J].Clin Gastroenterol Hepatol, 2013, 11 (1) :81-87.
|
|
[3] ZEUZEM S, ANDREONE P, POL S, et al.Telaprevir for retreatment of HCV infection[J].N Engl J Med, 2011, 364 (25) :2417-2428.
|
|
[4]CUNNINGHAM M, FOSTER GR.Efficacy and safety of telaprevir in patients with genotype 1 hepatitis C infection[J].Therap Adv Gastroenterol, 2012, 5 (2) :139-151.
|
|
[5]PARK C, JIANG S, LAWSON KA.Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1:a meta-analysis[J].J Clin Pharm Ther, 2014, 39 (1) :14-24.
|
|
[6]GHANY MG, NELSON DR, STRADER DB, et al.An update on treatment of genotype 1 chronic hepatitis C virus infection:2011practice guideline by the American Association for the Study of Liver Diseases[J].Hepatology, 2011, 54 (4) :1433-1444.
|
|
[7]MANNS M, MARCELLIN P, POORDAD F, et al.Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-nave patients:results from QUEST-2, a phaseⅢtrial[C].48th Annual Meeting of the European Association for the Study of the Liver (EASL) , Amsterdam, the Netherlands, 2013.
|
|
[8]RODRIGUEZ-TORRES M, STOEHR A, GANE EJ, et al.Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis[J].Clin Gastroenterol Hepatol, 2013.[Epub ahead of print]
|
|
[9]MARCELLIN P, COOPER C, BALART L, et al.Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection[J].Gastroenterology, 2013, 145 (4) :790-800.
|
|
[10]LAWITZ E, MANGIA A, WYLES D, et al.Sofosbuvir for previously untreated chronic hepatitis C infection[J].N Engl J Med, 2013, 368 (20) :1878-1887.
|
|
[11] RODRIGUEZ-TORRES M, RODRIGUEZ-ORENGO J, GAGGAR A, et al.Sofosbuvir and peginterferon alfa-2a/ribavirin for treatment-naive genotype 1-4 HCV-infected patients who are coinfected with HIV[C].IDWeek 2013 (Infectious Diseases Society of America) , San Francisco, CA, 2013.
|
|
[12]POCKROS PJ, JENSEN D, TSAI N, et al.JUMP-C:a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naive HCV genotype 1/4 patients[J].Hepatology, 2013, 58 (2) :514-523.
|
|
[13]LAWITZ E, RODRIGUEZ-TORRES M, RUSTGI VK, et al.Safety and antiviral activity of ANA598 in combination with pegylated interferon a 2A plus ribavirin in treatment-naive genotype-1chronic HCV patients[C].45th Annual Meeting of the European Association for the Study of the Liver, Vienna (Austria) , 2010.
|
|
[14]SARRAZIN C, ZEUZEM S.Resistance to direct antiviral agents in patients with hepatitis C virus infection[J].Gastroenterology, 2010, 138 (2) :447-462.
|
|
[15]LOHMANN V, HOFFMANN S, HERIAN U, et al.Viral and cellular determinants of hepatitis C virus RNA replication in cell culture[J].J Virol, 2003, 77 (5) :3007-3019.
|
|
[16] APPEL N, ZAYAS M, MILLER S, et al.Essential role of domainⅢof nonstructural protein 5A for hepatitis C virus infectious particle assembly[J].PLoS Pathog, 2008, 4 (3) :e1000035.
|
|
[17]POL S, GHALIB RH, RUSTGI VK, et al.Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection:a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial[J].Lancet Infect Dis, 2012, 12 (9) :671-677.
|
|
[18]FISCHER G, GALLAY P, HOPKINS S.Cyclophilin inhibitors for the treatment of HCV infection[J].Curr Opin Investig Drugs, 2010, 11 (8) :911-918.
|
|
[19]FLISIAK R, PAWLOTSKY J, CRABBE R, et al.Alisporivir (DEB025) plus peg-IFNα2a/ribavirin results in superior sustained virological response (SVR24) in chronic C genotype 1 treatment naive patients[C].Ann Meet Eur Assoc Study Liver, 2011.
|
|
[20]GUEDJ J, YU J, LEVI M, et al.Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in HCV genotype 2/3 patients[J].Hepatology, 2014, 59 (5) :1706-1714.
|
|
[21]COELMONT L, HANOULLE X, CHATTERJI U, et al.DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A[J].PLoS One, 2010, 5 (10) :e13687.
|
|
[22]GANE EJ, STEDMAN CA, HYLAND RH, et al.Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection[J].Gaetroenterology, 2014, 146 (3) :736-743.
|
|
[23]LOK A, GARDINER D, HEZODE C, et al.Sustained virologic response in chronic HCV genotype (GT) 1-infected null responders with combination of daclatasvir (DCV;NS5A inhibitor) and asunaprevir (ASV;NS3 inhibitor) with or without peginterferon alfa-2a/ribavirin (PEG/RBV) [C].63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) , Boston, MA, 2012.
|
|
[24]SULKOWSKI MS, GARDINER DF, RODRIGUEZ-TORRES M, et al.AI444-040 study group sustained virologic response with daclatasvir plus sofosbuvir±ribavirin (RBV) in chronic HCV genotype (GT) 1-infected patients who previously failed telaprevir (TVR) or boceprevir (BOC) [C].48th Annual Meeting of the European Association for the Study of the Liver, Amsterdam, The Netherlands, 2013.
|
|
[25]SARRAZIN C, KIEFFER TL, BARTELS D, et al.Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir[J].Gastroenterology, 2007, 132 (5) :1767-1777.
|
DownLoad: